#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15018	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1995	747.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1388	1388	C	873	C	778	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15018	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1995	747.8	0	HET	.	.	.	C451T,A	.	451	451	C	655	655	C	895	C,T,A	606,183,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27358	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3551	768.9	0	.	n	.	0	T695C	SNP	695	695	T	1051	1051	C	819	C	722	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27358	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3551	768.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2327	2327	C	858	C	762	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27358	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3551	768.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2401	2401	A	877	A	778	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27358	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3551	768.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2953	2953	C	882	C	784	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1964	folP	855	855	100.0	folP.l15.c17.ctg.1	1305	149.3	1	SNP	p	R229S	1	.	.	685	687	AGC	911	913	AGC	179;176;175	A;G;C	164;161;157	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5302	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3439	153.8	1	SNP	p	S91F	1	.	.	271	273	TTC	565	567	TTC	167;172;175	T;T;C	153;157;158	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5302	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3439	153.8	1	SNP	p	D95G	1	.	.	283	285	GGC	577	579	GGC	179;180;180	G;G;C	161;161;159	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5302	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3439	153.8	1	SNP	p	G95N	0	.	.	283	285	GGC	577	579	GGC	179;180;180	G;G;C	161;161;159	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1580	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1321	119.2	1	SNP	p	G45D	0	.	.	133	135	GGC	420	422	GGC	200;200;202	G;G;C	179;178;179	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	768	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	844	89.9	0	.	n	.	0	A197.	DEL	197	197	A	483	483	A	180	A	160	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5932	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2925	202.3	1	SNP	p	D86N	0	.	.	256	258	GAC	604	606	GAC	244;245;249	G;A;C	217;211;221	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5932	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2925	202.3	1	SNP	p	R87I	0	.	.	259	261	CGT	607	609	CGT	251;251;251	C;G;T	224;222;218	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5932	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2925	202.3	1	SNP	p	R87W	0	.	.	259	261	CGT	607	609	CGT	251;251;251	C;G;T	224;222;218	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5932	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2925	202.3	1	SNP	p	S87R	1	.	.	259	261	CGT	607	609	CGT	251;251;251	C;G;T	224;222;218	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5932	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2925	202.3	1	SNP	p	S88P	0	.	.	262	264	TCC	610	612	TCC	253;253;248	T;C;C	224;227;222	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4194	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2591	161.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1531	1533	GGC	207;206;206	G;G;C	185;182;182	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1188	1190	GCC	225;224;227	G;C;C,G	199;198;202,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1191	1193	ATG	226;227;227	A;T;G	200;198;200	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1203	1205	ACC	217;215;215	A;C;C	183;183;183	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1203	1205	ACC	217;215;215	A;C;C	183;183;183	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1704	1706	ACC	231;229;227	A;C;C	192;194;198	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1758	1760	GCG	177;175;173	G;C,A;G	158;155,1;154	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1758	1760	GCG	177;175;173	G;C,A;G	158;155,1;154	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1881	1883	GGT	182;178;176	G,A;G,A;T	160,1;157,1;155	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1890	1892	AGC	171;165;164	A;G;C	151;144;143	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3814	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2270	167.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1908	1910	CCG	136;140;140	C,G;C,G;G	88,12;94,2;97	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5810	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3036	190.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1673	1675	CCG	214;214;214	C;C;G,C	178;184;177,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2526	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1810	138.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	608	608	C	193	C	163	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2944	porB1b	1038	1038	99.9	porB1b.l6.c30.ctg.1	1558	187.9	0	.	p	.	0	G48E	NONSYN	142	144	GGA	497	499	GAA	240;240;242	G;A;A	218;218;223	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2944	porB1b	1038	1038	99.9	porB1b.l6.c30.ctg.1	1558	187.9	1	SNP	p	G120K	1	.	.	358	360	AAG	713	715	AAG	236;237;236	A;A;G	217;216;214	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2944	porB1b	1038	1038	99.9	porB1b.l6.c30.ctg.1	1558	187.9	1	SNP	p	N121D	0	.	.	361	363	AAC	716	718	AAC	239;241;240	A;A;C	216;218;216	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2944	porB1b	1038	1038	99.9	porB1b.l6.c30.ctg.1	1558	187.9	1	SNP	p	A121N	1	.	.	361	363	AAC	716	718	AAC	239;241;240	A;A;C	216;218;216	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11184	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4927	226.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1104	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	848	129.2	1	SNP	p	V57M	1	.	.	169	171	ATG	390	392	ATG	248;247;250	A;T;G	222;221;226	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
